pSivida Corp. Company Profile (NASDAQ:PSDV)

Analyst Ratings

Consensus Ratings for pSivida Corp. (NASDAQ:PSDV) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.00 (83.25% upside)

Analysts' Ratings History for pSivida Corp. (NASDAQ:PSDV)
Show:
DateFirmActionRatingPrice TargetActions
7/20/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/29/2015Ladenburg ThalmannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/17/2015Northland SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/7/2015MLV & Co.Reiterated RatingBuy$6.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for pSivida Corp. (NASDAQ:PSDV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
9/7/2016        
5/5/2016Q3($0.20)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q116($0.15)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/9/2015Q415($0.14)($0.17)$409.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q315($0.13)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2015($0.13)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q3 14($0.12)$0.67$25.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/9/2014Q414($0.15)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q314($0.15)($0.03)$0.55 million$2.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/7/2014Q214($0.13)($0.13)$430.00 million$0.59 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q1($0.14)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/25/2013Q413($0.12)($0.17)$0.65 million$0.49 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2013Q2 2013($0.11)$0.63 million$0.59 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q113($0.10)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for pSivida Corp. (NASDAQ:PSDV)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20161($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for pSivida Corp. (NASDAQ:PSDV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for pSivida Corp. (NASDAQ:PSDV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/4/2016Leonard S. RossVPSell5,000$4.70$23,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2015Leonard S. RossVPSell33,950$5.39$182,990.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2015Paul AshtonCEOSell120,000$5.39$646,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Paul AshtonCEOSell10,000$4.27$42,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Paul AshtonCEOSell10,000$4.78$47,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Paul AshtonCEOSell10,000$4.37$43,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Paul AshtonCEOSell10,000$4.32$43,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2014Paul AshtonCEOSell7,000$4.00$28,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Lori FreedmanVPSell7,900$4.00$31,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Paul AshtonCEOSell7,700$4.00$30,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014Lori FreedmanVPSell11,700$4.02$47,034.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014Paul AshtonCEOSell11,800$4.02$47,436.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2012Paul HopperDirectorBuy10,000$1.68$16,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for pSivida Corp. (NASDAQ:PSDV)
DateHeadline
07/27/16 06:20 PMpSivida (PSDV) Reports First Medidur Phase 3 as PU Treatment Met ... - StreetInsider.com
07/27/16 03:25 PMpSivida Corp.: Strong price momentum but will it sustain? -
07/27/16 08:59 AMIncremental Risk of Elevated IOP Relative to Control Decreases Through Last Follow-up Visit
07/27/16 07:08 AMpSivida's Medidur™ Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001) - [at noodls] - July 27, 2016 WATERTOWN, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, ...
07/20/16 06:48 PMpSivida Corp. Stock Volatility Hits An Unsually High Level - CML News
07/20/16 11:50 AMETF’s with exposure to pSivida Corp. : July 20, 2016 -
07/20/16 08:47 AMpSivida (PSDV) Announces Presentation of New Tethadur bioerodible Tech Data; Retained High Activity Noted - StreetInsider.com
07/20/16 08:47 AMEarnings Focus and Crowd Sourced Sentiment Review for pSivida Corp. (NASDAQ:PSDV) - TGP
07/20/16 07:00 AMData Shows pSivida’s Tethadur™ Provides Prolonged, Sustained Release of Avastin® With High Drug Efficacy - [GlobeNewswire] - WATERTOWN, Mass., July 20, 2016-- pSivida Corp., a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that new data from preclinical studies of ...
07/19/16 06:04 PMNew Broker Ratings For PSivida Corp. (PSDV) - FTSE News
07/19/16 04:41 AMBlazing Stocks Calls Bulls- Shaw Communications (NYSE:SJR), pSivida Corp. (NASDAQ:PSDV), HEALTHSOUTH ... - Seneca Globe
07/18/16 03:03 PMPSIVIDA CORP. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financ -
07/17/16 10:06 AMNext Weeks Broker Price Targets For PSivida Corp. (PSDV) - Fiscal Standard
07/15/16 04:57 PMPSivida To Locate Research And Product Development Activities In U.S. Facility
07/15/16 11:04 AMFollowing Unusual Volume on Shares of pSivida Corp. (NASDAQ:PSDV) - Engelwood Daily
07/15/16 11:04 AMpSivida (PSDV) Says Investigator-Sponsored Phase 2 Study Results Show Medidur Fully Controlled Uveitis - StreetInsider.com
07/15/16 07:28 AMpSivida Corp. Announces Plan to Consolidate all Research and Development in Current U.S. Facility - [at noodls] - July 15, 2016 WATERTOWN, Mass., July 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, ...
07/14/16 06:11 PMStudy Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology
07/14/16 11:18 AMInvestigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve - [at noodls] - July 14, 2016 WATERTOWN, Mass., July 14, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, ...
07/14/16 10:01 AM11:01 am pSivida announces the results from an investigator-sponsored Phase 2 study of Medidur showed no recurrence of uveitis in 11 eyes treated with Medidur during the 2 years following implantation, while six of 10 fellow eyes without Me -
07/14/16 10:00 AMInvestigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve - [GlobeNewswire] - WATERTOWN, Mass., July 14, 2016-- pSivida Corp., a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that the results from an investigator-sponsored ...
07/13/16 08:53 AMpSivida Corp. (NASDAQ:PSDV) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 08:53 AMPSivida Corp. (PSDV) Updated Price Targets - FTSE News
07/12/16 06:12 PMOption Market: pSivida Corp. Risk Hits An Elevated Level - CML News
07/12/16 06:12 PMPsivida Corporation (NASDAQ:PSDV) Shorted Shares Increased 8.42% After Market Selling - Consumer Eagle
07/08/16 05:56 PMCan pSivida Corp. (NASDAQ:PSDV) Improve on the Earnings Front? - Engelwood Daily
07/08/16 05:56 PMCompany Stock Focus for pSivida Corp. (NASDAQ:PSDV): Which Way Will Shares Head? - Press Telegraph
07/08/16 05:56 PMPSivida Corp. (PSDV) Current Analyst Ratings - Fiscal Standard
07/08/16 07:41 AMpSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™ Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting - [at noodls] - July 8, 2016 WATERTOWN, Mass., July 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, ...
07/06/16 10:37 AMpSivida Corp. (NASDAQ:PSDV) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/05/16 05:42 PMStock Trending Upwards in Trading: pSivida Corp. (NASDAQ:PSDV) - Telanagana Press
07/05/16 05:42 PMShare Performance Recap for: pSivida Corp. (NASDAQ:PSDV) - Press Telegraph
07/05/16 05:42 PMpSivida Corp. (NASDAQ:PSDV)'s Company Shares Decreased 15.95% After Low Volatility - Engelwood Daily
07/05/16 05:42 PMBroker Outlook For The Week Ahead PSivida Corp. (PSDV) - Fiscal Standard
07/05/16 10:24 AMPromising Results for Potential Sustained Treatment of Wet AMD Using a TKI
07/05/16 10:24 AMpSivida (PSDV) Completes Two Preclinical Studies Utilizing Durasert Technology
07/03/16 05:17 PMpSivida Corp. (NASDAQ:PSDV) Earnings Glance and Target Price Review - Engelwood Daily
07/02/16 05:34 PMCompany Stock Lower on the Week pSivida Corp. (NASDAQ:PSDV) - Engelwood Daily
07/02/16 05:34 PMWill pSivida Corp. (NASDAQ:PSDV) Surprise Analysts? - Investor Newswire
06/30/16 06:13 PMUpdate on Stock Volatility for: pSivida Corp. (NASDAQ:PSDV) - Engelwood Daily
06/29/16 05:50 PMpSivida Corp. (NASDAQ:PSDV) Company Rating and Target Watch - Telanagana Press
06/27/16 10:03 AMShare Update and Earnings Review for pSivida Corp. (NASDAQ:PSDV) - Press Telegraph
06/27/16 10:03 AMStock Volatility in Review: pSivida Corp. (NASDAQ:PSDV) - Engelwood Daily
06/03/16 08:50 AMShare Rating Focus on pSivida Corp. (NASDAQ:PSDV) - HNN - Share Rating Focus on pSivida Corp. (NASDAQ:PSDV)HNNPresently, Wall Street analysts have given a consensus stock rating of 1 on shares of pSivida Corp. (NASDAQ:PSDV). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus number is ...and more »
06/02/16 08:58 AMTarget Price and Stock Performance Rundown for pSivida Corp. (NASDAQ:PSDV) - HNN - Target Price and Stock Performance Rundown for pSivida Corp. (NASDAQ:PSDV)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, pSivida Corp. (NASDAQ:PSDV) shares ...and more »
06/02/16 08:58 AMPSivida Corp. (PSDV) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - PSivida Corp. (PSDV) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of pSivida Corp. (PSDV). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...
06/01/16 06:30 PMpSivida Corp. (NASDAQ:PSDV) Stock Update & Estimates - Stock Tick Tock - pSivida Corp. (NASDAQ:PSDV) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting pSivida Corp. (NASDAQ:PSDV) to post earnings of $-0.17 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
05/29/16 12:42 PMPerformance at a Glance on pSivida Corp. (NASDAQ:PSDV) - HNN - Performance at a Glance on pSivida Corp. (NASDAQ:PSDV)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how pSivida Corp. (NASDAQ:PSDV)'s stock has performed at various points in its past. Currently, the stock ...and more »
05/28/16 12:05 PMpSivida (PSDV) Fluctuates Upward; Deutsche Bank Doubles PT On Vivint Solar (VSLR) - Galaxy Stocks (press release) (registration) - pSivida (PSDV) Fluctuates Upward; Deutsche Bank Doubles PT On Vivint Solar (VSLR)Galaxy Stocks (press release) (registration)The price of pSivida Corp. (Nasdaq:PSDV) stock climbed $0.75 (or +24.19%) to $3.85, and a total of 355,191 of its shares were traded on Friday, a large increase in activity versus its average volume (3m) of 82,270. There appears to be no confirmed news ...
05/27/16 01:08 PMStock Rating Review for pSivida Corp. (NASDAQ:PSDV) - Wall Street Hints and News - Stock Rating Review for pSivida Corp. (NASDAQ:PSDV)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of pSivida Corp. (NASDAQ:PSDV). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus rating is ...and more »

Social

About pSivida Corp.

pSivida Corp. logopSivida Corp. is a biotechnology company, which is engaged in the development of sustained-release drug-delivery products for treating eye diseases. The Company offers products for treatment of back-of-the-eye diseases. The Company's lead development product, Medidur is used for posterior of the eye (posterior uveitis). Medidur is in Phase III clinical trials. The Company's pre-clinical development program is focused on developing products using its platform technologies, Durasert and Tethadur, to deliver drugs and biologics to treat ophthalmic diseases, such as wet and dry age-related macular degeneration (AMD), glaucoma and osteoarthritis, among others. Its Durasert technology platform delivers therapeutics for predetermined periods of time ranging from days to years. Its Tethadur technology system utilizes BioSilicon, nanostructured elemental silicon, designed to provide sustained delivery of biologic molecules, such as peptides, proteins and antibodies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PSDV
  • CUSIP:
Key Metrics:
  • Previous Close: $3.82
  • 50 Day Moving Average: $3.24
  • 200 Day Moving Average: $3.10
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $130.54M
  • Beta: 1.36
  • Current Year EPS Consensus Estimate: $-0.62 EPS
  • Next Year EPS Consensus Estimate: $-0.25 EPS
Additional Links:
pSivida Corp. (NASDAQ:PSDV) Chart for Friday, July, 29, 2016